Related Experiment Videos
Development of Recombinant Canarypox Viruses Expressing Immunogens
Débora Garanzini1,2, María Paula Del Médico-Zajac1,3, Gabriela Calamante4
1Instituto de Biotecnología, CICVyA-INTA, N. Repetto y de los Reseros, Hurlingham, Buenos Aires, Argentina.
Methods in Molecular Biology (Clifton, N.J.)
|April 5, 2017
Summary
Recombinant canarypox virus (CNPV) vaccines offer a safe and effective way to induce immune responses. This chapter details protocols for creating these valuable recombinant CNPV vectors for vaccine development.
Area of Science:
- Virology
- Vaccinology
- Molecular Biology
Background:
- Canarypox viruses (CNPV) are promising candidates for recombinant vector vaccines due to their ability to elicit protective immunity and their inherent safety profile, as they do not replicate in mammalian cells.
- CNPV and its recombinants can be handled under Biosafety Level 1 conditions, simplifying laboratory procedures.
- Currently, no commercial system exists for generating recombinant CNPV, necessitating adapted methodologies.
Purpose of the Study:
- To provide detailed protocols for the generation and characterization of recombinant canarypox viruses (CNPV).
- To adapt existing vaccinia virus (VV) methodologies for the development of recombinant CNPV.
- To facilitate the creation of novel CNPV-based vaccine vectors.
Main Methods:
- Adaptation of established vaccinia virus (VV) recombinant generation techniques.
- Detailed protocols for recombinant CNPV generation, including plaque isolation.
- Methods for molecular characterization, amplification, and purification of recombinant CNPV.
Main Results:
- Successfully adapted VV methodologies for recombinant CNPV production.
- Established protocols cover the complete workflow from generation to purification.
- The described methods enable the creation of safe and effective CNPV-based vaccine candidates.
Conclusions:
- The provided protocols enable the generation and characterization of recombinant canarypox viruses (CNPV).
- These methods facilitate the development of novel CNPV vector vaccines with a favorable safety profile.
- The adaptation of VV techniques offers a viable pathway for producing recombinant CNPV under standard laboratory conditions.